How to submit
- Download the GTOS Word template.
- Complete all fields in English.
- Save as .docx using the required file name.
- Upload via the submission form or send to
File Name: GTOS2027_Abstract_LastName.docx - Wait for notification before final poster preparation.
| Submission opens | 1 September 2026 |
| Submission deadline | 15 January 2027 |
| Notification of acceptance | 26 February 2027 |
Important Information on the Selection Process
All abstracts submitted to GTOS 2027 will be peer-reviewed and ranked according to scientific and translational merit. Each abstract will be reviewed by two independent reviewers, with final decisions confirmed by the GTOS Programme Committee.
Abstracts may be accepted in one of the following formats:
- Flash Poster Talk + Poster: Selected abstracts will be presented as a short 3-minute oral presentation during one of the GTOS Flash Poster Talk sessions and additionally as a poster.
- Poster Presentation: Accepted abstracts will be presented during the GTOS poster session and networking reception.
The final presentation format will depend on the review score, available programme capacity and the decision of the Programme Committee. Authors will be informed about the acceptance and presentation format by email.
Review Criteria
Each abstract will be assessed for:
- Relevance to GTOS
- Scientific or translational quality
- Innovation
Important
- The presenting author of an accepted abstract must register for GTOS 2027 and attend the meeting in Heidelberg.
- A presenting author may submit one abstract as presenting author, but may be listed as a co-author on additional submissions.
- Duplicate or substantially identical submissions should not be submitted.
- Abstracts should contain a clear scientific question or objective, appropriate methods or approach, results and a conclusion or translational message.
- Abstracts without sufficient scientific content or results may be rejected.
- The submitted version should be regarded as final after the submission deadline.
Where Does My Abstract Fit?
GTOS 2027 focuses on the translation of oligonucleotide-based therapeutic approaches, with the inaugural edition centered on rare neurological diseases. Please select the category that best reflects the main focus of your work. The categories are intended to help assign appropriate reviewers and organize accepted abstracts within the scientific programme.
1. Disease Translation
For work addressing the transition from disease biology and unmet need to a therapeutic concept. Examples include: Disease mechanisms and therapeutic rationale, target identification, indication selection, patient stratification, therapeutic amenability, unmet medical need, rare neurodevelopmental, movement, neuromuscular, channelopathy and neurometabolic disorders.
2. Preclinical Translation
For work focusing on the development and evaluation of oligonucleotide therapeutic strategies before clinical application. Examples include: ASO and other oligonucleotide modalities, design and screening strategies, in vitro and in vivo models, PK/PD and biodistribution, delivery, safety and off-target assessment, preclinical evidence packages, manufacturing-related translational considerations.
3. Clinical Translation
For work addressing clinical development and evaluation of oligonucleotide therapies. Examples include: Safety monitoring, biomarkers and target engagement, clinical trial design, endpoint selection, ,patient selection and treatment readiness, longitudinal follow-up, real-world evidence.
4. Implementation in Rare Neurological Disease
For work addressing how oligonucleotide therapies can be implemented in clinical practice, particularly for rare, ultra-rare and individualized treatments. Examples include: ASO treatments for rare diseases, named-patient approaches, individualized ASO treatments, case-selection frameworks, hospital implementation pathways, ethics and governance, informed consent, registries and long-term evidence generation.
5. Regulatory, HTA & Infrastructure
For work focusing on the systems required to translate oligonucleotide therapies into sustainable clinical use. Examples include: Regulatory pathways, scientific advice and agency interaction, quality and manufacturing requirements, evidence standards in very small populations, HTA and reimbursement, clinical and translational infrastructure, implementation pathways in Germany and Europe.
6. Cross-Cutting Perspectives
For relevant work that does not fit exclusively into one of the categories above or provides lessons from adjacent fields. Examples include: Other therapeutic modalities, platform approaches, international implementation models, non-commercial therapy development, new technologies, methodological or interdisciplinary approaches.
Important Information on the Selection Process
By submitting an abstract to GTOS 2027, you confirm that:
- The submitted information is accurate and all listed authors have approved the submission.
- You have checked the abstract carefully for scientific accuracy, author names, affiliations and language before submission.
- The abstract meets appropriate scientific and ethical standards.
- Any required approvals or permissions relating to patient information, images or other protected material have been obtained.
- The presenting author agrees to register for and attend GTOS 2027 if the abstract is accepted.
- Changes to the abstract can only be made until the submission deadline.
- Personal data submitted as part of the abstract process may be collected, stored and processed for the organization of GTOS 2027 in accordance with applicable EU-GDPR requirements.
- The title, author information and abstract content of accepted submissions may be used in the GTOS programme, website, digital programme materials and other conference communications.
- The submission and resulting presentation must be scientific, educational and non-promotional. Product advertising or content primarily intended to promote a specific commercial entity is not permitted.AI-based tools may be used for language support such as spelling, grammar or clarity. Responsibility for the scientific content, data, interpretation and conclusions remains entirely with the authors.